by Jeito Life | 22 Feb Tue | English
Paris, France, 22 February 2022 – Jeito Capital (“Jeito”), a leading independent private equity firm dedicated to biotech and biopharma, today announces that it has co-led a $65 million Series A financing round in EyeBiotech Limited (“EyeBio”), a privately held...
by Jeito Life | 17 Feb Thu | English
Paris, France, February 17, 2022 – Jeito Capital (“Jeito”), a leading independent private equity firm dedicated to biotech and biopharma, is strengthening its team with the appointments of Dr. Andreas Wallnoefer as Partner Investor and Isabelle...
by Jeito Life | 15 Feb Tue | English
Jeito Capital selected European clinical stage biotech NMD Pharma, based in Denmark, as its 7th investment and leads the new financing Proceeds will be used to progress clinical lead programs, expand the number of target indications, and enlarge R&D capabilities...
by Jeito Life | 29 Nov Mon | English
Quell Therapeutics is the world leader in developing engineered T-regulatory (Tregs) cell therapies for serious medical conditions driven by the immune system. Jeito continues to build a strong portfolio of companies with groundbreaking therapies in areas of high...
by Jeito Life | 13 Oct Wed | English
Partnership will allow SparingVision to develop novel genomic medicines for the treatment of ocular diseases utilizing Intellia’s proprietary CRISPR/Cas9 technology Jeito Capital selected SparingVision as its first French investment in October 2020, participating in a...
Recent Comments